Patents by Inventor Donald J. Kyle

Donald J. Kyle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10974081
    Abstract: The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: April 13, 2021
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen C. Harris, Ram P. Kapil, Donald J. Kyle, Garth Whiteside
  • Publication number: 20200345726
    Abstract: The disclosure relates to methods for treating or preventing an Insomnia Disorder by administering to a human in need thereof a compound of formula (I), or a compound of formula (IA), (IB), or (IC), or a solvate thereof, in a daily dose of from about 0.5 mg to about 6.0 mg. In certain embodiments, such compounds effectively treat or prevent an Insomnia Disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Application
    Filed: January 22, 2019
    Publication date: November 5, 2020
    Applicant: Purdue Pharma L.P.
    Inventors: Stephen C. HARRIS, Ram P. KAPIL, Donald J. KYLE, Garth WHITESIDE
  • Publication number: 20200276187
    Abstract: Disclosed in certain embodiments is a method of attenuating or preventing opioid-induced euphoria comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: March 24, 2020
    Publication date: September 3, 2020
    Applicant: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20200155542
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: July 31, 2019
    Publication date: May 21, 2020
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20190282836
    Abstract: The disclosure relates to methods for treating or preventing a sleep disorder by administering a compound of formula (1)(1), or a compound of formula (1A), (1B), (1C), (1D), (1E), or (1F) to an animal in need of such treatment. In certain embodiments, such compounds effectively treat or prevent a sleep disorder in the animal, while producing reduced side effects compared to previously available compounds.
    Type: Application
    Filed: July 25, 2017
    Publication date: September 19, 2019
    Inventors: Stephen C. HARRIS, Ram P. KAPIL, Donald J. KYLE, Garth WHITESIDE
  • Patent number: 10398690
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: December 18, 2017
    Date of Patent: September 3, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20190201410
    Abstract: This application relates to using trace amine associated receptor 1 (TAAR1) agonists and/or partial agonists for treating or preventing pain, especially neuropathic pain.
    Type: Application
    Filed: June 2, 2017
    Publication date: July 4, 2019
    Applicant: Purdue Pharma L.P.
    Inventors: Michele HUMMEL, Donald J. KYLE, Laykea TAFESSE, Garth WHITESIDE
  • Patent number: 10226457
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: March 12, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 10202344
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: February 12, 2019
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Patent number: 10149896
    Abstract: The invention provides for the synthesis of more effective generators of a T-cell immune response by providing peptide derivatives that are MHC class I-restricted antigens. The peptide derivatives of the present invention are prepared or derived from a parent peptide of 8 to 11 amino acid residues in length, wherein the peptide derivative contains a non-natural amino acid substituted in place of a naturally-occurring amino acid residue at one or more primary anchor positions in the parent peptide or at position 6, position 7, or the C-terminus.
    Type: Grant
    Filed: January 23, 2017
    Date of Patent: December 11, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Donald J. Kyle, Daniel A. Soltis, Lynda G. Tussey
  • Patent number: 10143696
    Abstract: Disclosed in certain embodiments is a method of decreasing gastric emptying comprising administering to a subject an effective amount of a sodium-channel blocker to decrease gastric emptying.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: December 4, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside, Nathan Lautermilch
  • Publication number: 20180193331
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: December 8, 2017
    Publication date: July 12, 2018
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20180104237
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Application
    Filed: December 18, 2017
    Publication date: April 19, 2018
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20180105561
    Abstract: The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels. The present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels, compositions and methods for providing analgesia by administering a peptide of the invention.
    Type: Application
    Filed: September 20, 2017
    Publication date: April 19, 2018
    Inventors: Jae Hyun Park, Donald J. Kyle
  • Patent number: 9931337
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: April 3, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michelle Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 9884059
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: February 6, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Publication number: 20180022699
    Abstract: The invention relates to aryl and heteroaryl substituted compounds of Formula (I), and pharmaceutically acceptable salts, prodrugs, or solvates thereof, wherein G, R1, and Z1-Z5 are defined as set forth in the specification. The invention is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present invention are especially useful for treating pain.
    Type: Application
    Filed: August 4, 2017
    Publication date: January 25, 2018
    Inventors: Donald J. Kyle, Chiyou Ni, Laykea Tafesse, Jiangchao Yao
  • Patent number: 9872856
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 23, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 9867817
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: January 16, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside
  • Patent number: 9855262
    Abstract: Disclosed in certain embodiments is a method of treating or preventing an opioid-induced adverse pharmacodynamic response comprising administering to a patient in need thereof an effective amount of buprenorphine.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: January 2, 2018
    Assignee: Purdue Pharma L.P.
    Inventors: Michele Hummel, Donald J. Kyle, Garth Whiteside